Destum Partners

Bridging the Gap Between Science and Business

NEWS

By

AcuraStem Enters into a License Agreement with Takeda to Advance PIKFYVE Therapeutics

Agreement enables the development of therapeutics, including AcuraStem’s AS-202
Candidate, an antisense oligonucleotide that suppresses levels of the PIKFYVE kinase.

MONROVIA, Calif., Sept. 25, 2023 — AcuraStem, a patient-based biotechnology
company pioneering how treatments are developed for neurodegenerative diseases,
announced today that it has entered into a license agreement with Takeda to develop
and commercialize AcuraStem’s PIKFYVE targeted therapeutics including AS-202, an
innovative antisense oligonucleotide (ASO) for the treatment of Amyotrophic Lateral
Sclerosis (ALS).

[Read more…] about AcuraStem Enters into a License Agreement with Takeda to Advance PIKFYVE Therapeutics

By

EffRx Pharmaceuticals Signs Exclusive Licensing Agreement With Radius Health To Commercialize BINOSTO® In The United States

Freienbach, September 19 , 2023 – EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the development and commercialization of musculoskeletal and rare diseases medications, today announced that it has signed an exclusive licensing and distribution agreement with Radius Health, Inc for Binosto® for the United States. BINOSTO® is indicated for the treatment of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. BINOSTO® provides an important once-weekly treatment option, particularly for patients with osteoporosis who may not be able to take alendronate tablets. Radius is a major player in the U.S. bone market and currently markets TYMLOS® for the treatment of osteoporosis in the U.S. BINOSTO® expands Radius’ presence in the treatment of bone health with a second product for the approximately 10 million people in the U.S. living with osteoporosis.

[Read more…] about EffRx Pharmaceuticals Signs Exclusive Licensing Agreement With Radius Health To Commercialize BINOSTO® In The United States

By

BIORCHESTRA Pens a Pact Worth up to $861M for Central Nervous System(CNS)-Targeted Polymeric Nanoparticle for Intravenous Delivery of Nucleic Acid Therapies

Exclusive Research and Option Agreement With Global Biopharmaceutical Company to Leverage BIORCHESTRA Targeting Technology Platform – BDDSTM – to Develop Nucleic Acid Therapies for Treatment of Neurological Disorders in Multiple Targets 

CAMBRIDGE, Mass. and DAEJEON, South Korea | March 27, 2023 – BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System (CNS) by leveraging the Biorchestra Drug Delivery System (BDDSTM), which combines targeted cell delivery capabilities and proprietary RNA chemistries to develop first-in-class therapeutics, today announced an exclusive research, option, and licensing agreement with a global biopharmaceutical company focused on developing transformative medicines. The companies will collaborate on an initial target with the option to expand the collaboration to include several additional targets. 

[Read more…] about BIORCHESTRA Pens a Pact Worth up to $861M for Central Nervous System(CNS)-Targeted Polymeric Nanoparticle for Intravenous Delivery of Nucleic Acid Therapies